Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) says it will take part in the Muskoka Capital Event, where senior representatives are scheduled to meet with investors in Minett, Ontario.
The event is organised by Capital Event Management Ltd. and is being hosted at the JW Marriott Rosseau Muskoka. The company’s announcement, dated September 23, 2026, contains conflicting event dates: its heading lists September 25 to 27, 2026, while the body refers to September 25 to 27, 2025.
#Company representatives to hold investor meetings
Microbix CEO Cameron Groome and Director of Product Management Pavel Zhelev are expected to conduct 18 one-on-one meetings with growth company investors during the formal part of the event.
The presentation materials used by the representatives are expected to be posted on Microbix’s website together with company information and financial disclosures.
#Microbix business profile
Mississauga, Ontario-based Microbix develops biological products used in diagnostic testing, laboratory quality assurance and disease management. Its proprietary antigens are used by approximately 100 diagnostics manufacturers.
The company also supplies QAPs quality assessment products and QUANTDx reference materials. Microbix says its products support assay development and validation, technician training, site onboarding, external quality assessment and quality assurance throughout testing workflows.
The release states that Microbix has 120 employees and fiscal 2025 revenues of C$18.6 million. Its products are available in more than 30 countries through international distribution partners.
Microbix says it maintains ISO 9001 and ISO 13485 certifications, U.S. FDA and Australian TGA registrations, Health Canada licences, and EU IVDR and CE-mark compliance. Its other proprietary products include Kinlytic urokinase and DxTM reagents for test-sample collection or processing.
#Forward-looking information
The company states that the release contains forward-looking information that is not a guarantee of future performance and is inherently uncertain. It cautions that actual events, conditions and results could differ materially from the estimates, beliefs, intentions and expectations expressed or implied.
The areas identified by Microbix include financial results and stability, development projects, regulatory compliance and approvals, access to and sales in foreign jurisdictions, production, currency exchange rates, maintaining profitability and adequate working capital, and raising further capital on acceptable terms or at all.
#Key Takeaways
- Microbix says it will present to investors at the Muskoka Capital Event in Minett, Ontario.
- CEO Cameron Groome and Director of Product Management Pavel Zhelev are scheduled for 18 one-on-one investor meetings.
- The announcement gives conflicting event dates, listing September 25 to 27, 2026 in its heading and September 25 to 27, 2025 in the body.
- Microbix reports 120 employees, fiscal 2025 revenues of C$18.6 million and product availability in more than 30 countries.
- The company says its forward-looking information is subject to material risks and uncertainty.
Original source: Read original article